NiTi Surgical Solutions Introduces Investigational Bowel Anastomosis Device
NiTi Surgical Solutions showcased new, investigational bowel anastomosis device at the American College of Surgeons (ACS) 95th Annual Clinical Congress. The device, which will be marketed as BowelRing, represents the company`s next advancement in its innovative BioDynamix Anastomosis Technology platform. NiTi`s unique line of products utilizes Nitinol-based elements to press together the ends of resected tissue, enabling natural reconnection and healing after removing a section as part of a surgery.


Findings from recently held two studies reveal that adalimumab reduces the risk of hospitalization as well as major surgery in patients suffering from Crohn’s disease (CD). The year long phase 3 trial (named CHARM) found that adalimumab was effective in improving the condition of patients with Crohn’s disease. There was a reduction in hospitalizations by half. Moreover, majority of Crohn’s disease patients undergo surgery. The results of the trial showed surgeries related to CD were reduced by as much as 90% in patients receiving adalimumab as compared to those receiving placebo. This makes the drug a cost-effective solution to the disorder. The study received support in the form of industry grants from
Israeli company 